trending Market Intelligence /marketintelligence/en/news-insights/trending/gxlddihnv1tnsdatxhtkcg2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Lixte Biotechnology names 2 directors


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Lixte Biotechnology names 2 directors

Lixte Biotechnology Holdings Inc. appointed Yun Yen and Winson Ho to its board.

Yen is president emeritus of Taipei Medical University and chair professor of the doctorate program for cancer biology and drug discovery.

Ho is a pediatric neurosurgery fellow at the University of Utah School of Medicine. He previously served as a research fellow at a division of the National Institutes of Health, and conducted research on Lixte's lead clinical compound.

New York-based Lixte Biotechnology develops treatments for cancer and nonmalignant diseases.